X

aPPD as a potential adjuvant to chemotherapy in reversing multidrug resistance

Scientists from Department of Surgery, University of British Columbia, Vancouver, British Columbia in Canada have discovered that 20S-Protopanaxadiol(aPPD) inhibits P-glycoprotein in multidrug-resistant cancer cells.

The growing resistance to anticancer drugs has become a global concern, threatening to the survival of huge numbers of cancer patients.The increasing number of the reports on the resistance to chemotherapy blew away patients’ hope for recovery from cancers.With this impetus to save people from desperate and painful cancers, researchers are always on the way to find new insights and methods towards cancer cures in their all efforts.

P-glycoprotein, known as multidrug resistance protein, is served as a carrier in humans which transports a wide variety of substrates across extra- and intracellular membranes. Unfortunately, some pharmaceutical drugs, a potential substrate, are pumped out, thus leading to a difficulty in drug absorbency and resistance. Some cancer can express large quantities of P-glycoprotein which make poor performances of anticancer drugs.

The research team focused on the study of the mechanism of action of ginsenosides which are natural compounds extracted from Araliaceae plants and exhibit strong anticancer efficacies. They explored whether aPPD also inhibits P‐gp activity, finding that, in addition to exerting cytotoxicity in cancer cells, aPPD shows a reversible nature of its P‐gp inhibition, meaning that aPPD can reverse the multidrug resistance of cancer cells.

This is not the first time that rare ginsenosides were found to exhibit reversible nature of multidrug resistance. Before this, South Korean researchers from Department of Pharmacology, College of Medicine, Chosun University had found that PPT ginsenosides can reverse multidrug resistance. Aimed to determine whether or not ginsenosides could reverse multidrug resistance mediated by P-Glycoprotein, they chose the daunorubicin- and doxorubicin-resistant acute myelogenous leukemia sublines (AML-2/D100 and AML-2/DX100) to test the effect of ginsenosides, and the findings showed that PPT Ginsenosides exert cytotoxicity on both sublines and were able to reverse resistance in the AML-2/D100 subline in a concentration-dependent manner.

“It is the first time that aPPD has shown a reversible nature of its P-gp inhibition. In addition to its pro-apoptotic nature, aPPD may be a potential new P-gp inhibitor for cancer treatment,” stated Prof zhao.